A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India

A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India

Saved in:

Bibliographic Details
Main Authors:	Sabha Mushtaq, Devraj Dogra, Naina Dogra
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-11-01
Series:	Przegląd Dermatologiczny
Subjects:	pemphigus biosimilar rituximab dexamethasone cyclophosphamide pulse glucocorticosteroids remission relapse
Online Access:	https://www.termedia.pl/A-retrospective-cohort-study-of-biosimilar-rituximab-therapy-in-pemphigus-experience-from-a-tertiary-care-hospital-in-North-India,56,55056,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment
by: Xiaolong Wang, et al.
Published: (2025-01-01)

Evaluation of the Effects of systemic Therapy on Inflammatory Markers and Disease Severity in Patients With Pemphigus
by: Mehmet Enes Güner, et al.
Published: (2025-01-01)

Review of modern techniques and analysis of patient outcomes with benign familial pemphigus Gougereau–Haley–Haley
by: Marianna B. Drozhdina, et al.
Published: (2024-12-01)

Persistent Nasal Skin Lesions in Pemphigus Patients and the Role of Methotrexate in Treatment: A Case Series Study
by: Mohamad Reza Kavyani, et al.
Published: (2025-01-01)

Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
by: Keerthi Talari, et al.
Published: (2021-01-01)

The utilization of the multimodal immunotherapy for the opsoclonus–myoclonus syndrome can reduce relapses and permanent neurological sequelae
by: Fang He, et al.
Published: (2025-02-01)

Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia
by: Tong-Yoon Kim, et al.
Published: (2025-01-01)

Life-threatening Pneumocystis jiroveci Pneumonia with Cytomegalovirus Coinfection in a Follicular Lymphoma Patient During Rituximab-based Chemotherapy
by: Mu-Chun Yang, et al.
Published: (2024-01-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
by: P. Rutgeerts
Published: (1998-01-01)

Immunosuppressive therapy of patients with pemphigus with ineffectiveness of systemic corticosteroids
by: Vadim V. Chikin, et al.
Published: (2024-12-01)

Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01)

The Impact of Air Pollution on Disease Activity in Bullous Pemphigoid and Pemphigus
by: Ron Feldman, et al.
Published: (2025-05-01)

Rituximab-induced serum sickness: Not so uncommon
by: Vikramraj K Jain
Published: (2018-01-01)

Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying Disease Showing Good Response to a New IVIg Preparation
by: Katharina Hogrefe, et al.
Published: (2025-01-01)

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01)

Direct immunofluorescence (DIF) versus immunohistochemical (IHC) staining of complements and immunoglobulins (Ig) in pemphigus group
by: Deepika Rana, et al.
Published: (2024-04-01)

A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic
by: Justin Baroukhian, et al.
Published: (2025-01-01)

Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India
by: Kalpana Babu, et al.
Published: (2025-02-01)

Paraneoplastic pemphigus involved oral mucosa only: a case report and literature review
by: Xixi Yu, et al.
Published: (2025-01-01)

Effects of infliximab biosimilar on retinal microvasculature in Crohn’s disease patients evaluated by optical coherence tomography angiography
by: Hesham M. El Mazar, et al.
Published: (2025-01-01)

Immunological Remission as a Basis for Dose Reduction of Immunosuppressors in Autoimmune Hepatitis: Results of Monocenter Surveillance Study
by: A. O. Bueverov, et al.
Published: (2024-03-01)

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)

The effectiveness of dexamethasone as a combination therapy for COVID-19
by: Namazi Nader
Published: (2022-09-01)

RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC
by: Rawanda Shamoon, et al.
Published: (2024-02-01)

Guillain–barre syndrome as a presenting feature of systemic lupus erythematosus in a child and it's complete resolution with rituximab treatment
by: Rahul Reddy, et al.
Published: (2019-01-01)

Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review
by: Jingliang Zhang, et al.
Published: (2025-02-01)

Efficacy of low-dose rituximab versus immunosuppressants in refractory orbital inflammatory pseudotumors with intracranial extension
by: Yuyu Li, et al.
Published: (2025-01-01)

Uveitis associated with elevation of intraocular pressure – what is the optimal therapy?
by: Agnieszka Kubicka-Trząska
Published: (2023-12-01)

Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches
by: Lucia Centanni, et al.
Published: (2025-01-01)

Prognostic value of circulatory growth factors to predict responsiveness to chemotherapy and remission status of patients with acute myeloid leukemia
by: Mohammad Ahmad Bani-Ahmad, et al.
Published: (2024-05-01)

Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality
by: Alejandra Adriana Cardoso de Castro, et al.
Published: (2025-01-01)

Rituximab (monoclonal anti-CD20 antibody) induced posterior reversible encephalopathy syndrome (PRES): A case report and literature review
by: Praveen K. Sharma, MD, et al.
Published: (2025-03-01)

Efficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis
by: Lin-ming Zhang, et al.
Published: (2025-01-01)

Outcome of therapy in biopsy proven lupus nephritis with cyclophosphamide or mycophenolate: Registry data from a South Indian tertiary care center
by: Keerthi Talari, et al.
Published: (2017-01-01)

Infections in systemic lupus erythematosus: A study of incidence and risk factors in 100 patients from western India
by: Ankan Jha, et al.
Published: (2022-01-01)

Bullous pemphigoid as a diagnostic and therapeutic challenge with a wide spectrum of dermatological symptoms
by: Przemysław Borowy, et al.
Published: (2025-01-01)

Rate and predictors of response to glucocorticoid therapy in patients of takayasu arteritis at a tertiary level hospital of Bangladesh: A longitudinal study
by: Farzana Shumy, et al.
Published: (2021-01-01)

Aseptic breast abscess syndrome as an example of neutrophilic dermatosis. Can an immune defect be the reason of a disease?
by: Przemysław Borowy, et al.
Published: (2024-11-01)